ReviewClinical, cosmetic and investigational dermatology2023

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.

Fabrizio Martora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.